Identifying and characterizing genomic safe harbors (gsh) in humans and murine genomes, and viral and non-viral vector compositions for targeted integration at an identified gsh loci
AssigneesGeneration Bio Co., University of Massachusetts
InventorsRobert M. Kotin, Evin Hildebrandt
Life of this patent
Estimating the term…
Abstract
The technology described herein relates to methods, compositions and in silico screening approaches for identifying and validating genomic safe harbors (GSHs) in mammalian genomes, including human genomes. Another aspects relates to recombinant nucleic acid vectors, including non-viral and viral vectors comprising a portion of the GSH loci, or gRNA sequences specific to a GSH loci, and methods for use of the vectors for insertion of a gene of interest into a GSH loci.
Claims94
A method to identify genomic safe harbor (GSH) regions in a mammalian genome, comprising;
- a. identifying the loci of the endogenous virus element (EVE) of the genome of ur-species or in related species within taxonomic rank order;
- b. identifying the interspecific conserved loci in the human or mouse genome;
- c. validating the loci as a genomic safe harbors in human or mouse germlines using at least one in vitro or in vivo assays selected from any one or more of:
- i. insertion of a marker gene into the loci in human cells and measure marker gene expression in vitro;
- ii. insertion of marker gene into orthologous loci in progenitor cells or stem cells and engraft the cells into immune-depleted mice and/or assess marker gene expression in all developmental lineages;
- iii. differentiate hematopoietic CD34+ cells into terminally differentiated cell types, wherein the hematopoietic CD34+ cells have a marker gene inserted into the loci identified in step b;
- or
- iv. generate transgenic knock-in mouse wherein the genomic DNA of the mouse has a marker gene inserted in the loci identified in step b, wherein the marker gene is operatively linked to a tissue specific or inducible promoter.
A method to identify genomic safe harbor (GSH) regions in a mammalian genome, comprising;
- a) performing comparative genomic approaches to:
- i) compare the interspecific introns of collinearly organized and/or synteny organized genes between species to identify an enlarged intron in one species relative to another species, and/or
- ii) compare intergenic distance (or space) between adjacent genes or selected genes that are collinearly organized or synteny organized between species to identify a large variation in the intergenic distance (or space);
- b) selecting the enlarged intron in step a(i) or intergenic space between selected genes in step a(ii) as a loci for a genomic safe harbor;
- c) validating the loci as a genomic safe harbor in human or mouse germlines using at least one in vitro or in vivo assays selected from any one or more of:
- i. insertion of a marker gene into the loci in human cells and measure marker gene expression in vitro;
- ii. insertion of marker gene into orthologous loci in progenitor cells or stem cells and engraft the cells into immune-depleted mice and/or assess marker gene expression in all developmental lineages;
- iii. differentiate hematopoietic CD34+ cells into terminally differentiated cell types, wherein the hematopoietic CD34+ cells have a marker gene inserted into the loci identified in step b;
- or
- iv. generate transgenic knock-in mouse wherein the genomic DNA of the mouse has a marker gene inserted in the loci identified in step b, wherein the marker gene is operatively linked to a tissue specific or inducible promoter.
The cell of claim 54, wherein the iPS cell is a patient-derived iPSC.
A cell comprising an integrated nucleic acid of interest or gene editing nucleic acid sequence located in a genomic safe harbor (GSH) loci selected from Table 1A or 1B.
A transgenic organism comprising an integrated nucleic acid of interest or gene editing nucleic acid sequence located in a genomic safe harbor loci selected from Table 1A or 1B.
A recombinant dependoparvovirus vector comprising a capsid, wherein the capsid comprises at least one GSH nucleic acid sequence.
Dependencies are inferred from the claim text.